ArticleBritish journal of cancer2007
Elevated serum matrix metalloproteinase 9 (MMP-9) concentration predicts the presence of colorectal neoplasia in symptomatic patients.
Article in British journal of cancer, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Risk prediction models for colorectal cancer in people with symptoms: a systematic review.BMC gastroenterology · 2016Pooled it
- Circulating proteins in response to combined-modality therapy in rectal cancer identified by antibody array screening.BMC cancer · 2016Trial
- Gingipain-Mediated Matrix Metalloproteinase-8 and -9 Activation in Oral Rinse Samples from Patients with Cancer: A Cross-Sectional Study.Dentistry journal · 2026Article
- Adverse birth outcomes are associated with circulating matrix metalloproteinases among pregnant women in Puerto Rico.Journal of reproductive immunology · 2023Article
- Development and Validation of Risk Prediction Models for Colorectal Cancer in Patients with Symptoms.Journal of personalized medicine · 2023Article
- Matrix metalloproteinase-9 (MMP-9) promoter -1562C/T functional polymorphism is associated with an increased risk to develop micropapillary thyroid carcinoma.Cancer biomarkers : section A of Disease markers · 2022Article
- Review
- Serum Matrix metalloproteinase-9 (MMP-9) can help identify patients with papillary thyroid cancer at high risk of persistent disease: Value and limitations of a potential marker of neoplasia.Cancer biomarkers : section A of Disease markers · 2020Observational
- Prediction of advanced colonic neoplasm in symptomatic patients: a scoring system to prioritize colonoscopy (COLONOFIT study).BMC cancer · 2019Article
- Proteomics analysis of colon cancer progression.Clinical proteomics · 2019Article
- The Association of Simultaneous Increase in Interleukin-6, C Reactive Protein, and Matrix Metalloproteinase-9 Serum Levels with Increasing Stages of Colorectal Cancer.Journal of oncology · 2018Article
- Profile of Expression of Genes Encoding Matrix Metallopeptidase 9 (MMP9), Matrix Metallopeptidase 28 (MMP28) and TIMP Metallopeptidase Inhibitor 1 (TIMP1) in Colorectal Cancer: Assessment of the Role in Diagnosis and Prognostication.Medical science monitor : international medical journal of experimental and clinical research · 2017Article
- Levels of matrix metalloproteinases differ in plasma and serum - aspects regarding analysis of biological markers in cancer.British journal of cancer · 2016Article
- A pilot study on faecal MMP-9: a new noninvasive diagnostic marker of colorectal cancer.British journal of cancer · 2016Article
- Plasma levels and diagnostic utility of VEGF, MMP-9, and TIMP-1 in the diagnosis of patients with breast cancer.OncoTargets and therapy · 2016Article
- Serum matrix metalloproteinase-9 in colorectal cancer family-risk population screening.Scientific reports · 2015Article
- The matrix metalloproteinase-7 and pro-enzyme of metalloproteinase-1 as a potential marker for patients with rectal cancer without distant metastasis.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2015Article
- Colorectal Cancer Biomarkers: Where Are We Now?BioMed research international · 2015Review
- Matrix metalloproteinases in cancer: their value as diagnostic and prognostic markers and therapeutic targets.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2013Review
- Assessing the value of matrix metalloproteinase 9 (MMP9) in improving the appropriateness of referrals for colorectal cancer.British journal of cancer · 2013Article
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Early detection of polyps or colorectal carcinoma can reduce colorectal carcinoma-associated deaths. Previous studies have demonstrated raised serum levels of matrix metalloproteinase 9 (sMMP-9) in a range of cancers. The aim of this study was to investigate the role of sMMP-9 levels in identifying colorectal neoplasia. Consenting patients donated a blood sample and were assessed by proforma-led history and physical examination. Samples were analysed for sMMP-9 concentration (enzyme-linked immuno-sorbant assay) and compared to final diagnoses. Logistic regression modelling determined independent factors associated with neoplasia. A total of 365 patients were recruited of whom 300 were analysed, including 46 normal controls. A total of 27 significant adenomas and 63 malignancies were identified. The median sMMP-9 concentration was 443 ng ml(-1) (IQR: 219-782; mean: 546). Patients with neoplasia had significantly elevated sMMP-9 levels (P<0.001). Logistic regression modelling identified elevated log(sMMP-9) as the most significant predictor of neoplasia (chi(2)=38.33, P<0.001). Other significant factors were age, sex, smoking history, abdominal pain and weight loss. The model accurately predicted neoplasia in 77.3% of cases. Sensitivity and specificity were 77.9 and 77.1%. sMMP-9 estimation can accurately stratify patient to low- or high-risk cohorts. Serum sampling is a potential means of avoiding unnecessary colonoscopy and reducing patient anxiety, iatrogenic morbidity and mortality, and cost.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.